Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
References
Additional references
Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
Comi G, Filippi M, Wolinsky JS, et al. European/Canadian Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging‐Measured Disease Activity and Burden in Patients with Relapsing Multiple Sclerosis. Annals of Neurology 2001;49:290‐97.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining hererogeneity and combining results from several studies in meta‐analysis. In: Egger M, Smith GD, Altman DG editor(s). Systematic reviews in Health Care. British Medical Journal, 2001:285‐312.
Durelli L, Verdun E, Clerico M, Versino E. Immunomodulatory agents in multiple sclerosis: clinical trials and therapy. San Diego: Gilman S, 2002.
Ferguson B, Matyszac MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393‐9.
Frohaman EM, Goodin DS, Calabresi PA, Corboy JR, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61(5):602‐11.
Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal appearing whithe matter in multiple sclerosis. Brain 1998;121:103‐13.
Jacobs L, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. Intramuscolar interferon beta 1‐a for disease progression in relapsing multiple sclerosis. Annals of Neurology 1996;39:285‐94.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces rate and improves disability in relapsing‐remitting multiple sclerosis: Results of a phase III multicenter, double‐blind, placebo‐controlled trial. Neurology 1995;45:1268‐76.
La Mantia L, Milanese C, D'Amico R. Meta‐analysis of clinical trials with copolymer 1 in multiple sclerosis. European Neurology 2000;43(4):189‐93.
Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta‐analysis of three double blind, randomized, placebo‐controlled clinical trials. Multiple Sclerosis 2003;9:349‐55.
Matthews WB, Acheson ED, Batchelor JR, Weller RO. McAlpine's Multiple Sclerosis. In: WB Matthews editor(s). Churchill Livingstone, Edinburgh, London, Melbourne, and New York, 1985:96‐145.
Mc Donald WI, Compston A, Edan G, et al. Recommended Diagnostic Criteria for Mutiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50:121‐27.
Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. The Cochrane Database of Systematic Reviews 2003, Issue 4.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols. Annals of Neurology 1983;13(3):227‐31.
The PRISMS Study Group. Randomised double‐blind placebo‐controlled study of interferon beta ‐1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498‐504.
Rice G PA, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing‐remitting multiple sclerosis. The Cochrane Database of Systematic Reviews 2001, Issue 4.
The IFNB Multiple Sclerosis Study Group. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Neurology 1993;43:655‐661.
Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine 2000;343:898‐904.
